The U.S. Centers for Disease Control and Prevention recently approved Novavax’s COVID-19 vaccine for emergency use in adolescents ages 12 through 17. The vaccine previously had been approved for those 18 and older.
The Novavax vaccine packages harmless proteins of the COVID-19 virus with an immune-boosting substance made from tree bark. Unlike previously approved mRNA and viral vector vaccine technologies that rely on the body to produce the COVID-19 spike protein,
Novavax is considered a traditional vaccine in that the spike protein is produced similarly to common vaccines against influenza, shingles, hepatitis B, tetanus, diphtheria and pertussis (whooping cough).
Vaccines like the Novavax COVID-19 vaccine that use protein subunit technology have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine.
Its approval adds another tool for fighting the pandemic and provides a more familiar type of COVID-19 vaccine technology for adolescents.
Schedule COVID-19 Vaccine Now